EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma

Lindsay Wong, Chisom Nwosu, Denise Nadora, Jimmy Wen, Akash Pathak, Eldo Frezza, Wei Tse Li

Clinical and Translational Discovery · 2026-04 · 6 (2)

DOI: 10.1002/ctd2.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Discovery, online erschienen am 17.04.2026. Verfasst von Lindsay Wong und 6 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cholangiocarcinoma (CCA) is the second most common liver malignancy after hepatocellular carcinoma and is difficult to treat with high rates of metastasis. The isocitrate dehydrogenase‐1 (IDH1) inhibitor ivosidenib has emerged as a promising second‐line therapy for CCA patients with IDH1 mutations.

Methods

We conducted a systematic review and meta‐analysis to examine ivosidenib's impact on patient survival in advanced‐stage CCA patients, following the Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines.

Results

A total of 317 patients across four studies were analysed in this review, with 256 ivosidenib‐treated patients and 61 placebo‐treated patients. Almost all patients have intrahepatic CCA. Ivosidenib was found to improve advanced CCA patient outcomes in median progression‐free survival (PFS) (Range: 2.7‐4.4 months), median overall survival (OS) (Range: 10.3–15 months), objective response rate (ORR) (Range: 2.4%–18.2%), and DCR (Range: 50.0%–63.6%), compared to outcomes in placebo‐treated advanced CCA (PFS = 1.4 months, OS = 7.5 months, ORR = 0% and DCR = 27.9%). Using individual‐level data and a random effects model, patient survival was calculated with a hazard ratio of 0.29 (95% confidence interval 0.21–0.42, p = 5.6 × 10 − 12). Common adverse events include nausea, vomiting, and abdominal pain, but QT prolongation was observed in between 5.5% and 9.1% of patients.

Conclusion

Our analysis suggests that pooled ivosidenib‐treated patients with advanced CCA possess better PFS and OS compared to placebo‐treated patients. However, studies combining ivosidenib with checkpoint blockade immunotherapy drugs or other targeted therapies have yet to be conducted.

Zitieren

APA

Wong, L., Nwosu, C., Nadora, D., Wen, J., Pathak, A., Frezza, E., & Li, W. T. (2026). Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma. Clinical and Translational Discovery, 6(2). https://doi.org/10.1002/ctd2.70143

Vancouver

Wong L, Nwosu C, Nadora D, Wen J, Pathak A, Frezza E, et al. Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma. Clinical and Translational Discovery. 2026;6(2). doi:10.1002/ctd2.70143

BibTeX
@article{Wong2026,
  author = {Wong, Lindsay and Nwosu, Chisom and Nadora, Denise and Wen, Jimmy and Pathak, Akash and Frezza, Eldo and Li, Wei Tse},
  title = {Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma},
  journal = {Clinical and Translational Discovery},
  year = {2026},
  volume = {6},
  number = {2},
  doi = {10.1002/ctd2.70143}
}
Kostenlos starten →